SPA
ADPT icon

Sherbrooke Park Advisers’s Adaptive Biotechnologies ADPT Stock Holding History

Sherbrooke Park Advisers’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,469
Closed -$147K – 577
2024
Q4 		$147K Buy
+24,469
New +$135K 0.05% 629
2024
Q2 		– Sell
-43,859
Closed -$141K – 873
2024
Q1 		$141K Buy
+43,859
New +$170K 0.03% 774
2023
Q3 		– Sell
-14,405
Closed -$96.7K – 496
2023
Q2 		$96.7K Buy
+14,405
New +$107K 0.05% 323

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sherbrooke Park Advisers's ADPT Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Adaptive Biotechnologies (ADPT) in Q1 2025, closing a stake of 24,469 shares — an estimated $147K sold.

Sherbrooke Park Advisers first reported a position in ADPT in Q2 2023 and held it in 3 quarters. The position peaked at $147K in Q4 2024. 225 funds tracked by Wall St. Rank hold ADPT as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Adaptive Biotechnologies position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 24,469 Adaptive Biotechnologies shares in Q1 2025, an estimated $147K.
  • Sherbrooke Park Advisers first reported a position in Adaptive Biotechnologies in Q2 2023 and held it in 3 quarters.
  • Sherbrooke Park Advisers's Adaptive Biotechnologies position peaked at $147K in Q4 2024.
  • 225 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.